| HOME >> BIOLOGY >> TECHNOLOGY |
VIENNA, Austria, September 25 /PRNewswire/ -- f-star, an antibody engineering company developing novel antibodies and antibody fragments based on its unique Modular Antibody Technology, today announced the appointment of Dr. Geert Mudde as Chief Scientific Officer. Dr. Mudde has over 20 years of experience in the biotech and pharmaceutical industry, specializing in preclinical research and development. He comes to f-star from Baxter BioScience, where he was Director of Discovery Research and Technical Assessment.
"Geert brings in a wealth of knowledge and experience in industrial research and development which will be of prime importance in shaping f-star's proprietary product development programs. We are delighted that he joins the executive management team at such a decisive stage of the Company's development," said Dr. Gottfried Himmler, CEO f-star.
"f-star has now established its proprietary Modular Antibody Technology as a unique antibody engineering technology with an excellent IP position. Based on the recent financing the Company is now prepared to move to the next stage and define its own development programs," said Dr. Geert Mudde, CSO. "I am excited to contribute to this important development step as part of the executive team," he added.
Dr. Mudde was one of the founders of f-star in 2006 and worked as a consultant to the Company since then. Prior to his most recent position at Baxter BioScience he held senior-level positions in the international biotechnology and pharmaceutical industry, including VP Research at Igeneon, Austria, Director Immunology at Ingenium Pharmaceuticals, Germany, and Director of Allergy & Inflammation/Immunology at Parke Davis in Paris, France. Before that he worked at Sandoz/Novartis and at the Swiss Institute for Allergy Research. Dr. Mudde received his PhD in immunology from the University Utrecht (The Netherlands).
About f-star
f-star is an antibody engineering company based in Vienna, Aus
'/>"/>
| SOURCE f-star Copyright©2007 PR Newswire. All rights reserved |
Related biology technology :
1. Detection of antibody-stained cell surface and intracellular protein targets with the Agilent 2100 bioanalyzer
2. Development of a Multiplex Bead-Based Assay for Antibody Screening of a Nonhuman Primate Colony on the Bio-Plex System
3. Mobile Phase Optimization for the Analysis of an Antibody-Based Fusion Protein and Aggregates using a TSKgel Super SW3000 Size-Exclusion Column
4. Biomedical engineering conference invites manufacturers
5. Re-engineering our economy to be sustainable and profitable
6. UW Biomedical Engineering awarded $2.9 million research grant
7. 3M donates $1.6 million to UW-Madison engineering building
8. Social engineering - Coming to an IT ship near you?
9. UW engineering career fair sees highest attendance in four years
10. Appleton engineering firm gets $250,000 in tax credits to build facility
11. UW-M engineering dean heads for promising medical business
| Copyright © 2003-2012 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |